Which of the following medications are Proton Pump Inhibitors (PPIs). (Select all that apply)

Proton pump inhibitors represent the most potent class of antisecretory agents by targeting the final stage of gastric acid production. These benzimidazole derivatives bind covalently to the H+/K+ ATPase enzyme system within the canalicular membrane of the parietal cell. This irreversible inhibition significantly elevates gastric pH, facilitating the healing of acid-peptic disorders such as erosive esophagitis and gastric ulcerations. A. Sucralfate: This agent is a sulfated aluminum complex that serves as a cytoprotective barrier rather than an acid inhibitor. It lacks the pharmacological mechanism to interact with the proton pumps of the parietal cells. Its primary action is localized to the ulcerated mucosal surface. B. Famotidine: This drug belongs to the H2-receptor antagonist class, which competitively inhibits histamine-induced acid secretion. While it reduces gastric acidity, its mechanism is distinct from the direct enzymatic blockade provided by proton pump inhibitors. It is typically less potent than PPIs. C. Maalox: This is a combination antacid containing aluminum hydroxide and magnesium hydroxide used for rapid chemical neutralization of existing hydrochloric acid. It does not prevent the formation of acid at the cellular level. Its therapeutic effects are transient and strictly intraluminal. D. Cimetidine: As the prototype H2-receptor blocker, cimetidine interferes with the histamine signaling pathway rather than the enzymatic pump. It is utilized for milder forms of acid reflux and peptic disease. It is not classified within the proton pump inhibitor category. E. Omeprazole: This was the first clinically available PPI and remains a cornerstone in treating Zollinger-Ellison syndrome and H. pylori infections. It requires an acidic environment for activation before binding to the secretory pumps. It provides sustained 24-hour acid suppression. F. Pantoprazole: Often used in acute clinical settings via intravenous or oral routes, this PPI is effective for preventing stress-induced ulceration. It demonstrates a high affinity for the proton pump and has fewer drug-drug interactions than earlier PPIs. It is a standard treatment for GERD. G. Esomeprazole: This is the S-isomer of omeprazole, designed to provide higher systemic bioavailability and more consistent acid control. It is highly effective in managing severe cases of gastroesophageal reflux and promoting the healing of mucosal erosions. It is a potent proton pump inhibitor.